Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: canadian real-world study

HIGHLIGHTS

• who: Paul K. Keith from the Thurgauerstrasse, Zurich, Switzerland have published the Article: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study, in the Journal: (JOURNAL) of 31/08/2018
• what: This study provides a detailed description of Ig20Gly infusion parameters tolerability and quality of life in clinical practice among patients with PID or SID switching to Ig20Gly from another SCIG and confirms the feasibility of infusing Ig20Gly via pump or manual administration. The CANadian CUvitru Non-interventional study (CANCUN; NCT03716700) was conducted with the primary objective of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.